- Home
- OBIO vs LARK Comparison
OBIO vs LARK Comparison
Compare OBIO & LARK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBIO
- LARK
- Stock Information
- Founded
- OBIO 2017
- LARK 1885
- Country
- OBIO United States
- LARK United States
- Employees
- OBIO N/A
- LARK N/A
- Industry
- OBIO Medicinal Chemicals and Botanical Products
- LARK Major Banks
- Sector
- OBIO Health Care
- LARK Finance
- Exchange
- OBIO Nasdaq
- LARK Nasdaq
- Market Cap
- OBIO 147.8M
- LARK 142.3M
- IPO Year
- OBIO N/A
- LARK N/A
- Fundamental
- Price
- OBIO $2.75
- LARK $26.87
- Analyst Decision
- OBIO Strong Buy
- LARK
- Analyst Count
- OBIO 4
- LARK 0
- Target Price
- OBIO $14.00
- LARK N/A
- AVG Volume (30 Days)
- OBIO 339.4K
- LARK 6.5K
- Earning Date
- OBIO 08-12-2025
- LARK 10-29-2025
- Dividend Yield
- OBIO N/A
- LARK 3.13%
- EPS Growth
- OBIO N/A
- LARK 42.91
- EPS
- OBIO N/A
- LARK 2.81
- Revenue
- OBIO $2,944,000.00
- LARK $62,413,000.00
- Revenue This Year
- OBIO $19.83
- LARK N/A
- Revenue Next Year
- OBIO $12.53
- LARK N/A
- P/E Ratio
- OBIO N/A
- LARK $9.56
- Revenue Growth
- OBIO 41.61
- LARK 11.63
- 52 Week Low
- OBIO $2.37
- LARK $18.81
- 52 Week High
- OBIO $6.50
- LARK $31.04
- Technical
- Relative Strength Index (RSI)
- OBIO 50.09
- LARK 56.36
- Support Level
- OBIO $2.65
- LARK $26.50
- Resistance Level
- OBIO $3.08
- LARK $27.18
- Average True Range (ATR)
- OBIO 0.16
- LARK 0.47
- MACD
- OBIO 0.03
- LARK 0.11
- Stochastic Oscillator
- OBIO 52.86
- LARK 85.32
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About LARK Landmark Bancorp Inc.
Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and southwest Kansas.